[1] Schmidt M,Burrell A,Roberts L,et al.Predicting survival after ECMO for refractory cardiogenic shock:The survival after veno-arterial-ECMO (SAVE)-score[J].Eur Heart J,2015,36(33):2246-2256.
[2] Szott L M,Horbett T A.Protein interactions with surfaces:cellular responses,complement activation,and newer methods[J].Curr Opin Chem Biol,2011,15(5):677-682.
[3] Tsai IY,Tomczyk N,Eckmann JI,et al.Human plasma protein adsorption onto dextranized surfaces:A two-dimensional electrophoresis and mass spectrometry study[J].Colloids Surf B Biointerfaces,2011,84(1):241-252.
[4] Jin J,Huang F,Hu Y,et al.Immobilizing PEO-PPO-PEO triblock copolymers on hydrophobic surfaces and its effect on protein and platelet:A combined study using QCM-D and DPI[J].Colloids Surf B Biointerfaces,2014,123:892-899.
[5] Carla T,André L,Ingrid L,et al.Effect of anticoagulation with citrate versus heparin on the adsorption of coagulation factors to blood purification resins with different charge[J].Biomacromolecules,2012,13(2):484-488.
[6] Gonçalves IC,Martins MCL,Barbosa JN,et al.Platelet and leukocyte adhesion to albumin binding self-assembled monolayers[J].J Mater Sci Mater Med,2011,22(9):2053-2063.
[7] Topper SR,Navitsky MA,Medvitz RB,et al.The Use of Fluid Mechanics to Predict Regions of Microscopic Thrombus Formation in Pulsatile VADs[J].Cardiovasc Eng Technol,2014,5(1):54-69.
[8] Berezhna LG,Ivanov AE,Leistner A,et al.Structure and biocompatibility of poly(vinyl alcohol)-based and agarose-based monolithic composites with embedded divinylbenzene-styrene polymeric particles[J].Prog Biomater,2013,2(1):1-8.
[9] Nowak J,Watala C,Boncler M.Antibody binding,platelet adhesion,and protein adsorption on various polymer surfaces[J].Blood Coagul Fibrinolysis,2014,25(1):52-60.
[10] Yoshida T,Yoshioka Y,Tochigi S,et al.Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice[J].Part Fibre Toxicol,2013,10(3):1-12.
[11] Roka-Moya YM,Zhernossekov DD,Grinenko TV.Plasminogen/plasmin influence on platelet aggregation[J].Biopolymers & Cell,2012,28(5)352-356.
[12] Hundalani SG,Nguyen KT,Soundar E,et al.Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation[J].Pediatr Crit Care Med,2014,15(5):198-205.
[13] Zieger B.Hämorrhagische diathesen im kindesalter[M].Berlin Heidelberg:Springer,2010.
[14] Wang S,Chin BJ,Gentile F,et al.Potential danger of pre-pump clamping on negative pressure-associated gaseous microemboli generation during extracorporeal life support—An in vitro study[J].Artif Organs,2016,40(1):89-94.
[15] Soininen A,Levon J,Katsikogianni M,et al.In vitro adhesion of staphylococci to diamond-like carbon polymer hybrids under dynamic flow conditions[J].J Mater Sci Mater Med,2011,22(3):629-636.
[16] Reininger AJ.Thrombusformation im Blutfluss[M].Berlin Heidelberg:Springer,2010.
[17] Nunes AJ,Hruczkowski J,Macarthur RG.781 Edmonton experience with venovenous extracorporeal membrane oxygenation in critically ill adults with severe respiratory failure[J].Can J Cardiol,2012,28(5):399.
[18] Apostolakis EE,Koletsis EN,Baikoussis NG,et al.Strategies to prevent intraoperative lung injury during cardiopulmonary bypass[J].J Cardiothorac Surg,2010,5(1):1-9.
[19] Scaglione F.New oral anticoagulants:comparative pharmacology with vitamin K antagonists[J].Clin Pharmacokinet,2013,52(2):69-82.
[20] Kusajima K,Hoashi T,Kagisaki K,et al.Clinical experience of more than 2 months usage of extracorporeal membrane oxygenation (Endumo©4000) without circuit exchange[J].J Artif Organs,2014,17(1):99-102.
[21] Yamashita A,Nagae C,Mori M,et al.Analysis of Anticoagulant Effect of Unfractionated Heparin by Using Thrombin Generation Assay in Vitro[J].J St Marianna University,2015,6(1):15-21.
[22] Grieshaber P,Bakchoul T,Wilhelm J,et al.Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery[J].J Thorac Cardiovasc Surg,2015,150(4):967-973.
[23] Morrissey JH.Polyphosphate multi-tasks[J].J Thromb Haemost,2012,10(11):2313-2314.
[24] Worm M,Köhler EC,Panda R,et al.The factor XⅡa blocking antibody 3F7:a safe anticoagulant with anti-inflammatory activities[J].Ann Transl Med,2015,3(17):247.
[25] Keyl C,Zimmer E,Bek MJ,et al.Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia[J].Thromb Haemost,2016,115(6):1081-1089.
[26] Mirdamadi A.Dabigatran,a direct thrombin inhibitor,can be a life-saving treatment in heparin-induced thrombocytopenia[J].ARYA Atheroscler,2013,9(1):112-114.
[27] Walker GM,Davis CF.Extra-corporeal Membrane Oxygenation[M].London:Springer,2009.
[28] Datta J,Phillips SE,Yang EY.Association of high ventilator pressures with the development of chronic pulmonary hypertension in congenital diaphragmatic hernia patients requiring ECMO[J].Pediatr Surg Int,2012,28(10):977-982.
[29] Tagawa T.Protease inhibitor nafamostat mesilate attenuates complement activation and improves function of xenografts in a discordant lung perfusion model[J].Xenotransplantation,2011,18(6):315-319.
[30] Lim JY,Kim JB,Choo SJ,et al.Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin[J].Ann Thorac Surg,2016,102(2):534-549.
[31] Park SJ,Kim JB,Jung SH,et al.Outcomes of extracorporeal life support for low cardiac output syndrome after major cardiac surgery[J].J Thorac Cardiovasc Surg,2014,147(1):283-289.
[32] Major TC,Brisbois EJ,Jones AM,et al.The effect of a polyurethane coating incorporating both a thrombin inhibitor and nitric oxide on hemocompatibility in extracorporeal circulation[J].Biomaterials,2014,35(26):7271-7285.
[33] Goldstein B,Baldassarre J,Young JN.Effects of inhaled nitric oxide on hemostasis in healthy adults treated with heparin:a randomized,controlled,blinded crossover study[J].Thromb J,2012,10(1):1-10.
[34] Suchyta DJ,Handa H,Meyerhoff ME.A nitric oxide-releasing heparin conjugate for delivery of a combined antiplatelet/anticoagulant agent[J].Mol Pharm,2014,1(2):645-650.
[35] Meyerhoff ME,Reynolds MM,Frost M,et al.Method of increasing biocompatibility of medical device by generating nitric oxide[P].US:8034384 B2,2011.
